Connecticut Headlines logo

17-11-2026 Tuesday

4:49:18 PM

MEDDDICAL Expands Patient Data Advisory for Pharmaceutical Product Launches

Nov 17, 2026

As competition intensifies and new therapies enter the market, MEDDDICAL is expanding its patient data advisory services to help pharmaceutical teams improve launch forecasts, identify treatment gaps, and make more informed commercialization decisions.

-- MEDDDICAL has expanded its patient data advisory service as pharmaceutical and MedTech organizations face growing pressure to improve product launch forecasts and demonstrate value in competitive healthcare markets. The service helps teams use aggregated patient data and real-world evidence (RWE) to assess commercial opportunities, understand treatment patterns, and make informed market entry decisions.

According to IQVIA's 2026 analysis, 73 novel active substances were launched globally in 2025, exceeding the previous decade's annual average. As new therapies enter the market, pharmaceutical organizations must assess patient demand, competing treatments, and reimbursement requirements before committing substantial resources to commercialization.

Traditional launch forecasts often rely on clinical trial populations, epidemiological estimates, and historical sales data. Although valuable, these sources may not fully capture how patients receive care in routine healthcare settings. Inaccurate assumptions about eligible patient populations can affect demand projections, resource allocation, and market access strategies.

MEDDDICAL's advisory service helps organizations identify appropriate aggregated patient datasets and analytical approaches. Health insurance claims data can provide insights into diagnosed populations, treatment pathways, healthcare utilization, and unmet medical needs, offering a clearer understanding of potential market opportunities.

These insights can improve patient population sizing and demand forecasting by showing how many patients receive relevant treatments and where gaps in existing care may exist. They also help commercial teams evaluate opportunities across different geographic markets.

The service supports competitive analysis and reimbursement planning. Understanding existing therapies, prescribing patterns, and healthcare resource use can help organizations assess product differentiation and prepare evidence relevant to health technology assessment and payer discussions.

“A successful pharmaceutical launch starts with understanding the patients a new therapy is intended to reach,” said a MEDDDICAL spokesperson. “Aggregated patient data helps organizations move beyond theoretical market estimates, identify real treatment needs, and make better-informed decisions about where to focus their launch efforts.”

By incorporating real-world patient insights earlier, pharmaceutical organizations can reduce uncertainty, improve resource allocation, and develop launch strategies grounded in actual healthcare utilization.

About MEDDDICAL

MEDDDICAL is a leading health market intelligence advisory that works with pharmaceutical partners to accelerate drug development and market access. With a multidisciplinary team of health economists, statisticians, and data scientists, MEDDDICAL specialises in analysing real-world evidence for its partners to facilitate better health outcomes for patients around the world.

Further information is available at https://medddical.com/data-enrichment-for-pharma/data-driven-product-launch-planning-with-aggregated-patient-data/

Contact Info:
Name: Rainer Muller
Email: Send Email
Organization: MEDDDICAL
Address: Aptos 221 Edificio D2C, Sotogrande, Cadiz 11310, Spain
Website: https://medddical.com

Source: NewsNetwork

Release ID: 89209907

Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.